以下文章来源于途深智合，作者途深智合

    近日，AI蛋白质设计公司，途深智合宣布完成天使+轮融资，投资方包括锡创投和上海艾特海浦。

    随着人工智能技术的发展，推动了AI For Science领域的行业进步。尤其是在蛋白质设计这一领域。蛋白质作为自然界中最重要的一类分子，横跨合成生物、医药等领域。诸多AI蛋白质设计模块的发布，弥补了传统蛋白质设计在研发时间、效率等方面的不足。但AI模型的复杂度高、数据依赖性强、多任务的迁移难度高等问题，导致AI蛋白质设计的渗透率仍有非常大的提升空间。

    途深智合的核心团队基于自身多年的学术成果和研发能力，开发了蛋白质设计的Colipot平台TourSynbio™；涵盖了蛋白质折叠、逆折叠、分子对接等各个模块的诸多模型，包括公司自主研发的全新蛋白质设计模型Grade-IF，蛋白改造模型 LaGDif，蛋白设计智能体 AutoPE，蛋白序列大模型 FalconProtein等等。可通过简单的多轮对话，完成蛋白质设计改造。

    王宇光 途深智合创始人、上海交大副教授

    今年诺贝尔化学奖授予了蛋白质AI设计领域的相关团队，这一成就充分展示了AI技术在蛋白质工程和生物制药中的巨大潜力。作为AI For Science领域的创新者，途深智合自主研发的TourSynbio™平台，正是应对这一技术革新的成果。通过该平台，我们能够利用对话式AI模型，在短时间内以纯干实验方式生成大量具有巨大潜力的蛋白质序列，显著提升蛋白质的活性、稳定性和产量。

    Recently, AI protein design company Toursun Synbio announced the completion of its Angel+ round of financing, with investors including Wuxi Venture Investment and Shanghai Aitehaipu.

    The development of artificial intelligence technology has driven industry progress in the field of AI For Science. Particularly in the field of protein design, proteins, as one of the most important classes of molecules in nature, span synthetic biology, medicine, and other fields. The release of many AI protein design modules has made up for the shortcomings of traditional protein design in terms of research and development time and efficiency. However, issues such as the high complexity of AI models, strong data dependence, and the difficulty of multi-task transfer have left significant room for improvement in the penetration rate of AI protein design.

    The core team of Toursun Synbio, based on their years of academic achievements and R&D capabilities, has developed the Colipot platform TourSynbio™ for protein design; it covers various models in modules such as protein folding, inverse folding, and molecular docking, including the company's independently developed new protein design model GradeIF, Protein Modification Model LaGDif, Protein Design Agent AutoPE, Protein Sequence Large Model FalconProtein. It can complete protein design and modification through simple multi-round dialogue.

    Wang YuguangThe founder of Toursun Synbio and an associate professor at Shanghai Jiao Tong University

    "The Nobel Prize in Chemistry this year was awarded to the team related to protein AI design, a feat that fully demonstrates the tremendous potential of AI technology in protein engineering and biopharmaceuticals. As an innovator in the field of AI For Science, Toursun Synbio's independently developed TourSynbio™ platform is a result of responding to this technological innovation. Through this platform, we can use conversational AI models to generate a large number of protein sequences with great potential in a purely dry experimental manner in a short time, significantly enhancing the activity, stability, and yield of proteins.

    Our technology has been widely applied in various fields such as food, medical aesthetics, and medicine, aiding in the design and development of new products. Looking ahead, we will continue to promote the innovative development of artificial intelligence-driven protein engineering and biopharmaceuticals."

关于诚美资本

是一家拥有深厚科技及产业背景的赋能型股权投资机构。核心团队由科技创新产业领军企业家、顶尖技术专家和资深投资家组成，具有深厚产业资源和丰富资本市场实战经验，团队过往投资业绩优秀。已在信创赛道投资多个细分领域头部企业，同时与三大电信运营商、北邮、中科院等国家级机构和院校常年保持深度合作，能够及时准确把握行业发展趋势和动向，以资源优势深度协同与赋能。